期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替吉奥与5-氟尿嘧啶联合奥沙利铂治疗晚期胃癌的疗效比较 被引量：2

下载PDF
导出
摘要 目的探讨替吉奥与5-氟尿嘧啶联合奥沙利铂治疗晚期胃癌的疗效比较。方法收集2007年5月至2011年5月在本院肿瘤内科住院患者38例,所有研究对象经手术或胃镜组织学病理确诊为晚期胃癌患者。根据化疗方案分为2组,试验组为替吉奥+奥沙利铂组,共15例,对照组为5-氟尿嘧啶+奥沙利铂+亚叶酸钙组,共23例。采用χ2检验对2组研究对象的毒性反应进行比较;然后采用KaplanMeier法绘制生存曲线,Log-rank检验进行单因素分析,比较2组药物的PFS及生存期的差异。结果 2组研究对象不同化疗方法治疗后发现,试验组中位PFS为12.4个月,对照组中位PFS为9.3个月,经Log-rank检验发现差异有统计学意义(P<0.05)。而2组患者的生存时间分别为(14.7 vs 12.9),差异无统计学意义(P>0.05)。结论替吉奥联合奥沙利铂方案与5-氟尿嘧啶+奥沙利铂+亚叶酸钙方案相比,近期治疗效果较好,但是总体生存时间差异较小。
作者 邱纯
机构地区 海南省人民医院肿瘤内科
出处 《中国医药指南》 2014年第6期103-104,共2页 Guide of China Medicine
关键词 替吉奥 5-氟尿嘧啶 奥沙利铂 治疗 晚期胃癌 疗效比较
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Kato T, Shimamoto Y, Uchida J, et al.Possible regulation of 5-fluorouracil induced neuro-and oral toxicities by two biochemical modulators consisting of S-l,a new oral formulation of 5 -fluorouracil[J].Anticancer Res,2001,21(3B):1705-1712.
  • 2Tanabe K,zuki T,kumoto N,et al.Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer:a retrospective analysis[J]. World J Surg Oncol,2010,8(1):40.
  • 3Ajani JA,Rodriquez W, Bodoky G,et al.Multicenter phase rrl comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J].J Clin Oncol,2010,28(9):1547-1553.
  • 4Kim H,Lee G,Oh SY, et al.A phase II study of S-1 and oxalipla tin(SOX)combination chemotherapy as a first-line therapy for patients with advanced gastric cancer[J].Invest New Drugs,2012, 30(1):350-356.
  • 5Ajani JA,Rodriguez G,Bodoky G.et al.Multicenter phase 11I comparison of cisplatin/S-1 (CS)with cisplatin/5-FU(CF)as first-line therapy in patients with advanced gastric cancer (FLAGS)[C].San Francisco:ASCO Gastrointestinal Cancers Symposium Meeting,2009.
  • 6郭志强,许宁.替吉奥联合奥沙利铂治疗老年晚期胃癌的临床研究[J].当代医学,2012,18(36):134-135. 被引量：18
  • 7董静波,李雁,翁国爱,殷晓玲,阮捷,郑军状.替吉奥联合奥沙利铂治疗进展期胃癌安全性评价[J].肿瘤学杂志,2011,17(4):253-256. 被引量：26
  • 8Sato Y,Takayama T,Sagawa T,et al.Phase II study of S-I,docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J].Cancer Chemother Pharmacol,2010,66(4):721-728.

二级参考文献27

  • 1Trotti A,Colevas AD, Seteser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment [J]. Semin Radiat Oncol, 2003, 13(3):176-181.
  • 2Tanabe K. Suzuki T, Tokumoto N,et al.Combination therapy with doeetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis[J]. World J Surg Oncol, 2010,8:40.
  • 3Higgie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and it metabolites in plasma, urine, and bile [J]. Cancer Res, 1987,47 (8): 2203-2206.
  • 4Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil [J]. Eur J Cancer, 1994,30A(10): 1517-1522.
  • 5Fukushima M, Shimamoto Y, Kato T,et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. of 5-fluorouracil [J].Anticancer Drugs, 1998,9 (9): 817-823.
  • 6Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical moderators [J]. Anticancer Drugs, 1996,7(5): 548-557.
  • 7Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group [J]. Oncology, 2000, 58 (3): 191- 197.
  • 8Ajani JA, Rodriquez W, Bodoky G, et al. Muhicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial [J]. J Clin Oncol, 2010,28(9): 1547-1553.
  • 9Fuse N, Fukuda H, Yamada Y, et al. Updated results of randomized phase Ⅲ study of 5-fluorouracil alone versus combination of irinotecan and cisplatin versus S-1 alone in advanced gastric cancer (JCOG 9912) [J]. J Clin Oncol (Meeting Abstracts), 2009, 27(15s):4514.
  • 10Kawai H, Ohtsu A, Boku N, et al. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey[J]. Gastric Cancer, 2003,6 (Suppl 1):19-23.

共引文献39

同被引文献17

引证文献2

二级引证文献7

中国医药指南
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部